B. Metzler seel. Sohn & Co. Holding AG bought a new position in Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm bought 66,028 shares of the company's stock, valued at approximately $2,129,000. B. Metzler seel. Sohn & Co. Holding AG owned approximately 0.05% of Surgery Partners as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Quarry LP grew its holdings in shares of Surgery Partners by 133.1% during the second quarter. Quarry LP now owns 3,082 shares of the company's stock valued at $73,000 after buying an additional 1,760 shares during the last quarter. KBC Group NV grew its stake in Surgery Partners by 31.8% during the 3rd quarter. KBC Group NV now owns 2,385 shares of the company's stock valued at $77,000 after purchasing an additional 576 shares during the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of Surgery Partners by 102.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 2,723 shares of the company's stock valued at $80,000 after purchasing an additional 1,375 shares during the period. Creative Planning purchased a new position in shares of Surgery Partners in the third quarter worth about $258,000. Finally, Versor Investments LP acquired a new stake in shares of Surgery Partners during the third quarter worth about $271,000.
SGRY stock opened at $23.36 on Friday. The company has a quick ratio of 1.66, a current ratio of 1.80 and a debt-to-equity ratio of 0.99. Surgery Partners, Inc. has a 52-week low of $21.36 and a 52-week high of $36.92. The company's 50-day simple moving average is $30.15 and its 200-day simple moving average is $28.40. The firm has a market cap of $2.97 billion, a P/E ratio of -48.67, a PEG ratio of 16.71 and a beta of 2.76.
Surgery Partners (NASDAQ:SGRY - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.06). The business had revenue of $770.40 million during the quarter, compared to analyst estimates of $768.99 million. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. The firm's revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.15 earnings per share. As a group, equities analysts forecast that Surgery Partners, Inc. will post 0.83 EPS for the current fiscal year.
Several equities analysts recently weighed in on the stock. Citigroup cut their price target on shares of Surgery Partners from $38.00 to $36.00 and set a "buy" rating on the stock in a report on Wednesday, August 7th. UBS Group began coverage on shares of Surgery Partners in a research note on Monday, October 14th. They issued a "buy" rating and a $38.00 price objective on the stock. Royal Bank of Canada decreased their target price on shares of Surgery Partners from $49.00 to $35.00 and set an "outperform" rating for the company in a research report on Wednesday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $43.00 price target on shares of Surgery Partners in a research report on Friday, October 4th. Finally, StockNews.com cut Surgery Partners from a "hold" rating to a "sell" rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $38.71.
View Our Latest Stock Analysis on SGRY
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Surgery Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surgery Partners wasn't on the list.
While Surgery Partners currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.